Theravance Biopharma (TBPH) Common Equity (2013 - 2026)
Theravance Biopharma's Common Equity came in at $289.71 million for Q2 2026, up 28.8% from $224.85 million a year earlier but down 0.3% from the prior quarter.
Powered by 
Analysis
Theravance Biopharma (TBPH) Common Equity (2013 - 2026) Analysis & Trends
At the end of FY2025, Theravance Biopharma's Common Equity was $296.72 million, up 69.0% from FY2024.
- Going back by year, Common Equity was $175.55 million in FY2024 (-17.6%), $213 million in FY2023 (-51.8%), $441.8 million in FY2022 and -$338.57 million in FY2021.
- The five-year range for quarterly Common Equity is -$351.45 million (Q1 2022) to $480.58 million (Q3 2022).
- Year-over-year, Common Equity has increased for five consecutive quarters, with growth averaging 19.2% over the last eight quarters.
- The fastest year-over-year change in Common Equity over five years came in Q1 2026 (growth of 75.1%), and the weakest in Q4 2023 (a decline of 51.8%).
- Business Quant data shows TBPH's Common Equity at $290.59 million (Q1 2026), $296.72 million (Q4 2025) and $232.68 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Theravance Biopharma | 883.70 Mn | -543.66 Mn | - | 289.71 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 289.71 Mn |
| Mar 31, 2026 | 290.59 Mn |
| Dec 31, 2025 | 296.72 Mn |
| Sep 30, 2025 | 232.68 Mn |
| Jun 30, 2025 | 224.85 Mn |
| Mar 31, 2025 | 165.98 Mn |
| Dec 31, 2024 | 175.55 Mn |
| Sep 30, 2024 | 185.65 Mn |
| Jun 30, 2024 | 193.69 Mn |
| Mar 31, 2024 | 204.87 Mn |
| Dec 31, 2023 | 213.00 Mn |
| Sep 30, 2023 | 246.13 Mn |
| Jun 30, 2023 | 280.16 Mn |
| Mar 31, 2023 | 370.56 Mn |
| Dec 31, 2022 | 441.80 Mn |
| Sep 30, 2022 | 480.58 Mn |
| Jun 30, 2022 | -349.81 Mn |
| Mar 31, 2022 | -351.45 Mn |
| Dec 31, 2021 | -338.57 Mn |
| Sep 30, 2021 | -323.59 Mn |
API Access
Theravance Biopharma Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=TBPH&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "TBPH", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=TBPH&period=max&api_key=YOUR_API_KEY");
const data = await res.json();